Is Angiotensin ii approved by the US FDA?

Drugs@FDA lists 3 application product lines for Angiotensin ii, including GIAPREZA (Prescription); ANGIOTENSIN ll ACETATE (Prescription); GIAPREZA (Discontinued).

Is Angiotensin ii authorised in the European Union?

EMA lists 1 centrally authorised medicine containing Angiotensin ii: Giapreza.

Active substance

Angiotensin ii

US FDA 3
EMA 1

Open in the medicines table

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
GIAPREZA	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML); EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	solution · intravenous	LA JOLLA PHARMA	Prescription	21 Dec 2017
ANGIOTENSIN ll ACETATE	EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	solution · intravenous	GLAND	Prescription	3 Jun 2025
GIAPREZA	EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	solution · intravenous	LA JOLLA PHARMA	Discontinued	21 Dec 2017

EMA European Union — centrally authorised medicines

Giapreza Paion Pharma GmbH · Authorised · authorised 23 Aug 2019 · ATC C09

Therapeutic indication (EMA)

Giapreza is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.